REGAIN THERAPEUTICS is a neurobiotech startup that is based on original research discoveries and patent-pending technologies developed at Karolinska Institute in Sweden in collaboration with The University of Cincinnati in the US.
Our mission is to advance meaningful, disease-modifying, evidence-based therapeutics for neurodegenerative diseases. Our vision is to make neurodegenerative diseases treatable and no longer terminal illnesses. Our technology is based on rethinking the mechanisms leading to neurodegeneration and completely redesigning the therapeutic approaches in order to replace and regain lost protein function rather than focusing only on protein aggregation.
Company Details
- Employees
- 2
- Founded
- 2020
- Address
- Hälsovägen, 7-9, Stockholm,141 57,sweden
- Industry
- Biotechnology
- Keywords
- Cell to Cure ApS.
- HQ
- Stockholm
Regain Therapeutics Questions
Regain Therapeutics's LinkedIn profile is https://se.linkedin.com/company/regain-therapeutics
Regain Therapeutics has
2 employees.
View email and phone details for 2
employees at Regain Therapeutics.
Regain Therapeutics's industry is
Biotechnology
Regain Therapeutics's top competitors are
Cell To Cure Aps,
Eribis Pharmaceuticals,
Brisk Bioscience,
Restore Vision,
Lithea Ab (Former Moroxite T Ab),
Synartro,
Innate Pharmaceuticals Ab,
Junvik Consulting,
Biotech-Igg,
Rare Thyroid Therapeutics.
Regain Therapeutics's categories are Biotechnology
Regain Therapeutics's founding year is 2020
